Get the Stockscreener App
6.24
4.52%
0.27
After Hours:
6.24
Journey Medical Corp stock is traded at $6.24, with a volume of 83,634.
It is up +4.52% in the last 24 hours and up +10.83% over the past month.
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's portfolio includes eight branded and three authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.
See More
Previous Close:
$5.97
Open:
$5.84
24h Volume:
83,634
Relative Volume:
1.41
Market Cap:
$137.93M
Revenue:
$56.13M
Net Income/Loss:
$-14.67M
P/E Ratio:
-8.4324
EPS:
-0.74
Net Cash Flow:
$-9.13M
1W Performance:
+1.63%
1M Performance:
+10.83%
6M Performance:
-0.48%
1Y Performance:
+83.53%
1-Day Range:
$5.64
$6.27
1-Week Range:
$5.51
$6.27
52-Week Range:
$3.2001
$6.8899
Journey Medical Corp Stock (DERM) Company Profile
Name
Journey Medical Corp
Sector
Phone
480-434-6670
Address
9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE
Compare DERM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DERM
Journey Medical Corp
|
6.24 | 137.93M | 56.13M | -14.67M | -9.13M | -0.74 |
|
ZTS
Zoetis Inc
|
163.50 | 72.50B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.98 | 47.08B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.16 | 45.99B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.29 | 17.52B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
312.26 | 13.78B | 2.76B | 1.11B | 898.10M | 22.77 |
Journey Medical Corp Stock (DERM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Jun-28-24 | Resumed | ROTH MKM | Buy |
| Dec-07-21 | Initiated | B. Riley Securities | Buy |
Journey Medical Corp Stock (DERM) Latest News
Q1 EPS Estimates for Journey Medical Reduced by Roth Capital - MarketBeat
Journey Medical appoints new COO amid growth phase - Investing.com
Journey Medical Strengthens Leadership: New COO to Drive Emrosi Launch Strategy - Stock Titan
Journey Medical (NASDAQ:DERM) Issues Earnings Results - MarketBeat
Q3 EPS Estimates for Journey Medical Boosted by Roth Capital - MarketBeat
FY2027 EPS Estimate for Journey Medical Decreased by Analyst - Defense World
FY2027 EPS Estimates for Journey Medical Reduced by Analyst - MarketBeat
Roth Capital Lowers Earnings Estimates for Journey Medical - Defense World
Q3 EPS Estimates for Journey Medical Increased by Analyst - Defense World
Journey Medical Corporation (NASDAQ:DERM) Q4 2024 Earnings Call Transcript - Insider Monkey
Journey Medical Reports 2024 Financial Results - TipRanks
Journey Medical’s Earnings Call Highlights MROSI Launch and Growth Potential - TipRanks
Journey Medical Corp (DERM) Q4 2024 Earnings Call Highlights: Strategic Launch of Emrosi and ... By GuruFocus - Investing.com Canada
Journey Medical earnings beat by $0.27, revenue fell short of estimates - Investing.com
Earnings call transcript: Journey Medical Q4 2024 reveals revenue miss By Investing.com - Investing.com South Africa
Earnings call transcript: Journey Medical Q4 2024 reveals revenue miss - Investing.com India
Earnings call transcript: Journey Medical’s Q4 2024 results highlight IMROCI launch - Investing.com
Journey Medical Corporation (DERM) Tops Q4 Earnings Estimates - Yahoo Finance
Journey Medical reports FY24 EPS (72c) vs (21c) last year - TipRanks
Journey Medical Corp reports results for the quarter ended December 31Earnings Summary - TradingView
FDA Green Light for Journey Medical's Rosacea Drug Reshapes 2024 Performance - Stock Titan
Earnings Scheduled For March 26, 2025 - Benzinga
New Study Compares Topical Serum and Pulse Light Therapy for Rosacea - Dermatology Times
Journey Medical launches Emrosi for the treatment of rosacea - Yahoo Finance
Power Up the Teyvat Journey: UGREEN Launches Genshin Impact Co-Branded Charging Collection - Yahoo Finance
23andMe's journey from DNA testing pioneer to bankruptcy - Yahoo Finance
Journey Medical Launches Emrosi, a Dual-Release Minocycline for Rosacea - Dermatology Times
Breakthrough: First Low-Dose Minocycline Treatment for Rosacea Shows Superior Results - Stock Titan
Short Interest in Journey Medical Co. (NASDAQ:DERM) Grows By 20.5% - MarketBeat
Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025 - Yahoo Finance
Journey Medical Sets Date for 2024 Annual Results: Dermatology Leader's Financial Update - Stock Titan
Journey Medical (DERM) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Claude Maraoui Sells 49,271 Shares of Journey Medical Co. (NASDAQ:DERM) Stock - MarketBeat
Journey Medical Co. (NASDAQ:DERM) CEO Sells $74,674.05 in Stock - MarketBeat
Journey Medical (DERM) to Release Quarterly Earnings on Thursday - Defense World
Stocks Rally as US Consumer Prices Cool - The Globe and Mail
Journey Medical Corporation to Participate in the 37th Annual ROTH Conference - The Manila Times
Journey Medical CEO Sets Stage for Major Updates at ROTH Conference - StockTitan
Journey Medical’s CEO sells $246,847 in stock By Investing.com - Investing.com South Africa
CEO Cashes Out: Major Stock Sale at Journey Medical Corp - TipRanks
Journey Medical’s CEO sells $246,847 in stock - Investing.com India
Journey Medical CEO Claude Maraoui sells shares worth $203,451 By Investing.com - Investing.com Canada
Journey Medical CEO Claude Maraoui sells shares worth $203,451 - Investing.com Australia
Journey Medical Co. (NASDAQ:DERM) CEO Sells $122,006.52 in Stock - MarketBeat
Claude Maraoui Sells 18,147 Shares of Journey Medical Co. (NASDAQ:DERM) Stock - MarketBeat
Dario Expands Behavioral Health Offerings to Include a Provider Network Through Strategic Arrangement with Rula - PR Newswire
Journey Medical CEO Claude Maraoui sells $360,761 in shares By Investing.com - Investing.com UK
Journey Medical Corp Stock (DERM) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.06%
0.52%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):